Intravitreal drug injections for age-related macular degeneration in at least one Canadian province have mushroomed in recent years, likely adding fuel to a controversy over off-label use of bevacizumab for this purpose.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — Washington might be ground zero for the nation’s political protests, but a planned Tuesday rally of labor and religious leaders who will attempt to “arrest” insurance executives sounds like it will be dramatic political theater even in this town.
No Comments »
Filed under: General Health News
Nearly a third of children with special healthcare needs are underinsured, and where a child lives strongly influences whether he or she will have adequate healthcare coverage, a new study found.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — The FDA has approved a new primary immunodeficiency treatment, Immune Globulin Subcutaneous 20% Liquid (Hizentra), as a once-weekly replacement therapy.
No Comments »
Filed under: Pharmacy News
Ischemix today announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule.
No Comments »
Filed under: Pharmacy News
The Journal of the American Academy of Dermatology (JAAD) has published Phase III data evaluating the safety and efficacy of imiquimod cream at two doses - 2.5% and 3.75% - administered daily on a 2-week treatment cycle. The study demonstrates that both formulations were superior to placebo, and that imiquimod 3.75% on a daily 2-week [...]
No Comments »
Filed under: Pharmacy News
The Journal of the American Academy of Dermatology has published Phase III data evaluating the safety and efficacy of imiquimod cream at two doses – 2.5% and 3.75% – administered daily on either 2-week or 3-week treatment cycles.
No Comments »
Filed under: Pharmacy News
INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary [...]
No Comments »
Filed under: Pharmacy News
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European [...]
No Comments »
Filed under: Pharmacy News
Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae - rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels…
No Comments »
Filed under: Pharmacy News
